Sutro Biopharma Q1 2022 revenue $5.9M; cash $192.1M; STRO-002 data expected H2 2022

SUTRO BIOPHARMA, INC.

2023-Q1 EPS reported -$0.84 revenue$5,897,000

Revenue $5.9M vs $14.7M YoY; operating expenses $45.0M vs $33.7M; net loss not stated directly.
Cash, cash equivalents and marketable securities $192.1M as of Mar 31, 2022; runway into H2 2023.
Phase 1 dose-expansion data for STRO-002 (ovarian cancer) expected H2 2022; regulatory meetings planned mid-2022.
First patient dosed in STRO-002 + bevacizumab combo trial; endometrial cohort enrolling.
Tasly amended STRO-002 license: $25M upfront, up to $350M in milestones; Tasly to fund Greater China development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.